Chimpanzee adenoviral vector-based filovirus vaccines

Abstract

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

What is claimed is: 
     
         1 . A method of inducing a protective immune response against an Ebola virus infection in a subject, the method comprising intramuscularly administering to the subject an effective amount of viral particles of a recombinant chimpanzee adenovirus type 3 (ChAd3) vector comprising a nucleic acid encoding an Ebola virus glycoprotein, followed by administering to the subject a prophylactically effective amount of a modified vaccinia virus Ankara (MVA) vector comprising a nucleic acid encoding the Ebola virus glycoprotein. 
     
     
         2 . The method of  claim 1 , wherein the Ebola virus is of species Zaire. 
     
     
         3 . The method of  claim 2 , wherein the Ebola virus glycoprotein is encoded by a polynucleotide sequence as shown in SEQ ID NO:10 (Z GP wild-type). 
     
     
         4 . The method of  claim 1 , wherein the Ebola virus is of species Sudan/Gulu. 
     
     
         5 . The method of  claim 4 , wherein the Ebola virus glycoprotein is encoded by a polynucleotide sequence as shown in SEQ ID NO: 11 or 13 (S/G GP codon-optimized or wild-type).